2025Äê3ÔÂ28ÈÕ£¬µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°µÏÍþÖÆµÏÍþ¹ú¼Ê¡±£¬03692.HK£©Ðû²¼£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáÆ¬£©6Ïî´´ÐÂÑо¿ÈëÑ¡ÓÚµ±µØÊ±¼ä3ÔÂ26-29ÈÕÔÚ·¨¹ú°ÍÀèÕÙ¿ªµÄÅ·Ö޷ΰ©´ó»á£¨ELCC£©£¬ÄÚÈݺ¸Ç°¢ÃÀÀÖ?ÔÚ·ÇСϸ°û·Î°©£¨NSCLC£©ÁìÓò¸¨ÖúÖÎÁÆ¡¢º±¼ûÍ»±äºÍÄ͵ÏÍþ¹ú¼ÊºóÖÎÁƵȷ½ÃæµÄÑÖ¤Ö¤¾Ý¡£ELCC´ó»áÊǷΰ©ÁìÓòµÄÖØÒª¹ú¼ÊѧÊõ»áÒéÖ®Ò»£¬Ö¼ÔÚΪÓë»áÕßÌṩÓëÐØ²¿Ö×ÁöÏà¹ØµÄ¸ßˮƽ½ÌÓý¿Î³ÌºÍ×îÐÂÑо¿½øÕ¹¡£
´´ÐÂÑо¿ 1
±êÌ⣺Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-¢óA Non-Small-Cell Lung Cancer: Updated Results From A Multiple-center Real-world Experience
°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÃô¸ÐÍ»±ä¢ñA2 -¢óAÆÚ·ÇСϸ°û·Î°©£ºÀ´×Ô¶àÖÐÐÄÕæÊµÊÀ½ç¾ÑéµÄ×îнá¹û
×÷ÕߣºÕÅÇìâù/ºú¼á Õã½´óѧҽѧԺ¸½ÊôµÚÒ»Ò½Ôº
´´ÐÂÑо¿ 2
±êÌ⣺MRD Evaluation of Aumolertinib in EGFR Mutation-positive Stage IB and Stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Single-arm, Open-lable Study
MRDÆÀ¹À°¢ÃÀÌæÄáÓÃÓÚEGFRÍ»±äÑôÐÔµÄIBÆÚºÍIA2-3ÆÚ½þÈóÐÔNSCLCÊõºó¸¨ÖúÖÎÁƵĶàÖÐÐÄ¡¢¿ª·Å¡¢µ¥±ÛÁÙ´²Ñо¿
×÷Õߣº³Ì³¬ ÖÐɽ´óѧ¸½ÊôµÚÒ»Ò½Ôº
´´ÐÂÑо¿ 3
±êÌ⣺Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A NSCLC with High Risk Factors and EGFR-sensitizing Mutations (APPOINT)
°¢ÃÀÌæÄḨÖúÖÎÁÆ¿ÉÇгýµÄIAÆÚº¬ÊµÌåºÍ/»ò΢ÈéÍ·³É·ÖEGFRÃô¸ÐÍ»±äµÄ·ÇСϸ°û·Î°©µÄÁÆÐ§ºÍ°²È«ÐÔÁÙ´²Ñо¿£¨APPOINT£©
×÷Õߣºº«±¦»Ý ÉϺ£ÐØ¿ÆÒ½Ôº
´´ÐÂÑо¿ 4
±êÌ⣺Safety and Efficacy of Aumolertinib Treatment in Patients with Advanced NSCLC Harboring 20ins and Uncommon EGFR Mutations (AIM)
°¢ÃÀÌæÄáÖÎÁÆÍíÆÚEGFR 20²åÈëºÍº±¼ûÍ»±äNSCLC»¼ÕßµÄÁÆÐ§ºÍ°²È«ÐÔ£¨AIM£©
×÷ÕߣºÕÅÁ¦/·½ÎÄ·å ÖÐɽÖ×ÁöÒ½Ôº
´´ÐÂÑо¿ 5
±êÌ⣺EGFR-mutant Advanced NSCLC Patients Continuously Benefit From Aumolertinib as Post Secone-Line Treatment
°¢ÃÀÌæÄá¶þÏßÖÎÁÆEGFR Í»±äNSCLC»¼Õß½øÕ¹ºóÈÔ»ñÒæ
×÷ÕߣºÁõÖÇ»ª ½Î÷Ê¡Ö×ÁöÒ½Ôº
´´ÐÂÑо¿ 6
±êÌ⣺High-Dose Aumolertinib as First-Line Treatment in Advanced NSCLC Patients Harboring EGFR 21L858R Mutation (AHEAD)
¸ß¼ÁÁ¿°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFR 21L85Í»±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼Õߣ¨AHEAD£©
×÷ÕߣºÁÖÁ¢Æ½ ·¬Ø®ÖÐÐÄÒ½Ôº
ELCC£¨European Lung Cancer Conference£¬Å·Ö޷ΰ©´ó»á£©ÊÇÓÉÅ·ÖÞÖ×ÁöÄÚ¿ÆÑ§»á£¨ESMO£©Óë¹ú¼Ê·Î°©Ñо¿Ð»á£¨IASLC£©ÁªºÏÖ÷°ìµÄȨÍþѧÊõ»áÒ飬ÖÂÁ¦ÓÚÍÆ¶¯·Î°©ÁìÓòµÄ»ù´¡Ñо¿¡¢ÁÙ´²ÕïÁÆÓë¶àѧ¿ÆÐ×÷·¢Õ¹¡£×Ô´´°ìÒÔÀ´£¬ELCCÒѳÉΪȫÇò·Î°©×¨¼Ò¡¢¿ÆÑÐÈËÔ±¼°Ò½ÁÆ´ÓÒµÕß½»Á÷Ç°ÑØ³É¹û¡¢·ÖÏíʵ¼ù¾ÑéµÄÖØÒª¹ú¼Êƽ̨¡£
×÷ΪÖйúÊ׸öÔÑÐÈý´úEGFR-TKI£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáÆ¬£©´´ÐÂÐÔµØÒýÈë»·±û»ù½á¹¹£¬¾ßÓÐÁ¼ºÃµÄÖ¬ÈÜÐÔºÍÎȶ¨ÐÔ£¬ÄܸüºÃµØÍ¸¹ýѪÄÔÆÁÕÏ£¬ÇÒ²»Á¼·´Ó¦·¢ÉúÂʵ͡£Ä¿Ç°£¬°¢ÃÀÀÖ?ÒÑÓÐÈýÏîÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬·Ö±ðÊÇ£º¶þÏßÖÎÁƼÈÍù¾EGFR-TKIÖÎÁƽøÕ¹£¬ÇÒT790MÍ»±äÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC»¼Õߣ¬Ò»ÏßÖÎÁƾßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬ÒÔ¼°º¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄNSCLC»¼ÕßÖÎÁÆ¡£
µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£
¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£
ÉùÃ÷£º
1¡¢±¾¹«¸æ½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£
2¡¢µÏÍþÖÆµÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍÆ¼ö¡£
3¡¢±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£
4¡¢ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£
ǰհÐÔ˵Ã÷
±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æä¸½Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆÎª¡°µÏÍþÖÆµÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖÆµÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£
±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄܰüÀ¨ÓëµÏÍþÖÆµÏÍþ¹ú¼ÊÒµÎñºÍ²úƷǰ¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆÚºÍ²ßÂÔÏà¹ØµÄǰհÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍÆ²âÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿ÆÑ§¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËØºÜ¶à¶¼ÊǵÏÍþÖÆµÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊÆ²»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£
µÏÍþÖÆµÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖÆµÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζÊ¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄǰհÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£